Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ ...
JNJ-63898081 (JNJ-081) is a bispecific antibody targeting PSMA-expressing tumor cells and CD3-expressing T cells, aiming to overcome immunosuppression and promoting antitumor …
JNJ-8081(JNJ-8081) - _专利_临床_研发 - synapse.zhihuiya.com
JNJ-8081: 一种ADCC、T淋巴细胞刺激剂药物，由Johnson & Johnson (Johnson & Johnson)公司最早进行研发，目前全球最高研发状态为无进展，作用机制: ADCC (抗体依赖的细胞毒作 …
JNJ-63898081 (JNJ-63898081) - 药物靶点：CD3 x PSMA_专利_临 …
JNJ-63898081 (JNJ-081) is a bispecific antibody targeting PSMA-expressing tumor cells and CD3-expressing T cells, aiming to overcome immunosuppression and promoting antitumor …
New Amivantamab Data from CHRYSALIS Study Show ... - Johnson & Johnson
2021年1月29日 · In this analysis of the Phase 1 CHRYSALIS study, investigators assessed the efficacy and safety of amivantamab in patients with NSCLC and EGFR exon 20 insertion …
JNJ-63898081 (JNJ-081) 是一种 PSMA 和 CD3 双特异性抗体，用 …
JNJ-081 是一种双特异性抗体，一个臂结合癌细胞上的 PSMA，另一个结合 T 细胞上的 CD3，以促进抗肿瘤活性。 方法： 这项 1 期剂量递增研究评估了在新型雄激素靶向治疗（例如，阿比 …
PSMA Protein, Cell and Beads | ACROBiosystems
Immobilized Monoclonal Anti-Human PSMA Antibody, Human IgG1 at 1 μg/mL (100 μL/well) can bind Biotinylated Cynomolgus PSMA Protein, His,Avitag (Cat. No. PSA-C82Q6) with a linear …
JNJ-8081 - Drug Targets, Indications, Patents - Synapse - Patsnap
2025年3月20日 · JNJ-8081: a ADCC, T lymphocytes stimulants Drug, Initially developed by Johnson & Johnson, Now, its global highest R&D status is Pending, Mechanism: ADCC …
Safety and preliminary clinical activity of JNJ-63898081 (JNJ-081), …
2022年2月16日 · JNJ-081 is a bispecific antibody with one arm binding PSMA on cancer cells and the other binding CD3 on T-cells to promote anti-tumor activity. Methods: This Phase 1 Dose …
ASCO GU 2022: Safety and Preliminary Clinical Activity of JNJ …
Study agent JNJ-081 was administered by intravenous (IV) infusion and then via subcutaneous (SC) route. Bayesian regression modeling was used for continuous reassessment during dose …
JNJ-63898081-靶点: PSMA_适应症: 肿瘤-临床_专利_批准
jnj-63898081是由强生创新制药研发的一种双特异性抗体，目前该药物最高研发阶段为临床一期，用于治疗肿瘤。 JNJ-63898081-靶点: PSMA_适应症: 肿瘤-临床_专利_批准
- 某些结果已被删除